Cannabinoid


Skye Bioscience Reports that Emerald Health Therapeutics Shareholders Voted in Favor of Plan of Arrangement with Skye

August 21st, 2022 - Ryan Allway

San Diego, California, August 19, 2022 — Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, reports that the shareholders of Emerald Health Therapeutics, Inc. (“Emerald” or the “Company”) (CSE: EMH; OTCQB: EMHTF) today approved the proposed plan of arrangement (the “Arrangement”) with Skye, with approval […]

Enveric Biosciences Announces Plans to Spin-off and Dividend its Cannabinoid Pipeline to Shareholders

May 11th, 2022 - Ryan Allway

The proposed spin-off would create two separate and distinct biotechnology companies, one developing next-generation psychedelic-inspired treatments and the other developing innovative cannabinoid treatments   NAPLES, FL, May 11, 2022 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced plans to transfer and spin-off its cannabinoid clinical development pipeline […]

Cannabics Pharmaceuticals Changes Name to CNBX Pharmaceuticals

March 28th, 2022 - Ryan Allway

TEL AVIV, Israel and BETHESDA, Md., March 28, 2022 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has changed its corporate name to “CNBX Pharmaceuticals Inc.”   CNBX Pharmaceuticals The Company’s new brand identity reflects the significant transformation that has already taken place across the […]

Skye Bioscience Reports Positive Results for SBI-100 in GLP Toxicology Study

February 16th, 2022 - Ryan Allway

  Initiation of Phase 1 clinical trial of SBI-100 ophthalmic nanemulsion expected in second the quarter of 2022   SAN DIEGO, CA, February 16, 2022 (GLOBE NEWSWIRE) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a pharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat diseases with significant unmet need, announced that it has completed a […]

Avicanna Enters into a Strategic Partnership with Tetra Bio-Pharma

February 14th, 2022 - Ryan Allway

TORONTO, Feb. 14, 2022 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has executed a non-binding term sheet with Tetra Bio-Pharma (“Tetra”) to assess […]

Canntab Announces Closing Of Convertible Debenture Private Placement, Warrant Expiry Extension And Corporate Update

February 1st, 2022 - Ryan Allway

TORONTO, Feb. 1, 2022 /PRNewswire/ — Canntab Therapeutics Limited (“Canntab” or the “Company”) (CSE:PILL) (OTCQB:CTABF) (FRA:TBF1), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the closing of a non-brokered private placement (the “Offering“) of secured convertible debentures of the Company (“Debentures“), pursuant to which the Company issued and […]

SciSparc Issued U.S. Patent For Its Core Technology That Treats Central Nervous Systems Disorders

January 4th, 2022 - Ryan Allway

  Patent Extends Protection for its Novel Compounds and Methods Already granted in Australia and Japan   TEL AVIV, Israel, Jan. 4, 2022 /PRNewswire/ — SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), marks today one of the […]

NutraLife Biosciences Partners with KOR Medical to Create Cannabinoid-Based Wellness Products

December 17th, 2021 - Ryan Allway

COCONUT CREEK, FL, Dec. 17, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — NutraLife Biosciences Inc. (OTC: NLBS) announces a strategic partnership with KOR Medical and completes an initial order for a line of cannabinoid-based wellness products. The initial products produced under this venture is a line of four ingestible items formulated to help improve overall health, including […]

Canntab Receives Medical Sales Licence from Health Canada

November 11th, 2021 - Ryan Allway

TORONTO, Nov. 11, 2021 /CNW/ – Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the “Company” or “Canntab”), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it has received its medical sales license from Health Canada for its Markham, Ontario facility, enabling the sale of all products directly to […]

BevCanna Sells Out Initial Shipment of Keef Brands, to British Columbia Liquor Distribution Branch

November 8th, 2021 - Ryan Allway

Demand for the award-winning beverage line prompts sell out of initial shipment online. VANCOUVER, British Columbia (Nov 8, 2021) — Emerging leader in innovative health and wellness beverages and products, BevCanna Enterprises Inc. ( CSE:BEV , Q:BVNNF , FSE:7BC ) (“ BevCanna ” or the “ Company ”) announced today that its initial shipment of Keef Brands award-winning line of cannabis-infused beverages to the British Columbia […]

Cannabics Pharmaceuticals Files 2 Provisional Patents On Compositions and Methods for Treating Cancer

October 18th, 2021 - Ryan Allway

TEL AVIV, Israel and BETHESDA, Md., Oct. 18, 2021 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has filed 2 new Provisional Patent applications on Compositions and Methods for treating cancer, including colorectal cancer and early intervention therapy for colorectal cancer patients.   […]

Skye Bioscience Announces $7.0 Million Registered Direct Offering

September 27th, 2021 - Ryan Allway

SAN DIEGO, CA, Sept. 27, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, today announced that it has entered into securities purchase agreements with several institutional investors, for the purchase and sale […]

LUFF Announces Equity Financing

September 2nd, 2021 - Ryan Allway

Vancouver, B.C. – TheNewswire – September 2, 2021 – Luff Enterprises Ltd., (CSE:LUFF) (CNSX:LUFF.CN)  (“LUFF” or the “Company”) is pleased to announce its intention to raise up to $750,000 by way of a non-brokered private placement of 28,846,154 units at a price of $0.026 per unit (the “Private Placement”).   Each Unit shall consist of one common share of the Company and […]

SciSparc Announces Updates Regarding its Phase IIb Study in Tourette Syndrome

July 26th, 2021 - Ryan Allway

SciSparc intends to evaluate the efficacy, safety and tolerability of its Proprietary Cannabinoid-Based Treatment- SCI-110 TEL AVIV, Israel, July 26, 2021 /PRNewswire/ — SciSparc Ltd. (OTCQB: SPRCY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced a number of updates regarding its Phase IIb clinical study in Tourette Syndrome using the proprietary […]

VEXT Announces Record Financial Results for Q1-2021

May 26th, 2021 - Ryan Allway

Revenue of US$9.2 million, +43% sequentially; Adjusted EBITDA1 of US$3.1 million, +27% sequentially. Adjusted fully diluted EPS of US$0.01. Phoenix dispensaries operated by VEXT generated successive record months in March 2021 and April 2021, with the trend continuing into May 20212. The Company will hold a conference call and webcast to discuss its Q1 financial results at 8:00 a.m. ET.   VANCOUVER, May 26, 2021 /CNW/ – Vext Science, […]

Iconic international cannabis brand, COOKIES, enters the CBD flower market

May 19th, 2021 - Ryan Allway

International cannabis brand COOKIES now offers consumers nationwide new access to COOKIES premium products with the launch of its novel CBD Flower line. After diligently looking and testing hundreds of batches, COOKIES has found the right cultivators to produce exceptional and unique CBD Flower genetics. These strains are hand-picked, indoor-grown and offer a flavorful experience. They provide a spectrum of wellness benefits […]

More Potent Than CBD, Naturally: CTFO Reveals Discovery of Stabilized Cannabinoid Acid Molecules

May 12th, 2021 - Ryan Allway

RENO, Nev., May 12, 2021 /PRNewswire/ — CTFO, Inc. (CTFO) set out to prove that its proprietary delivery oil 10xPURE™ could deliver bioavailable oily cannabinoids through your normally 60% aqueous body. CTFO announces a surprising and unexpected discovery: the ability to stabilize cannabinoid acid molecules such as CBDa, making the seemingly impossible, possible. This cannabinoid-acid stability milestone is supported by […]

Biocannabix Enters Into LOI With IAM Health GmbH

April 29th, 2021 - Ryan Allway

MONTREAL, April 29, 2021 (GLOBE NEWSWIRE) — Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), and its’ wholly-owned subsidiary, Biocannabix Health Corporation (the “BCX”), a company focused on Paediatric and Geriatric applications of Cannabinoid nutraceutical and medical food formulations, is delighted to announce that it has entered in a Letter of Intent (the “LOI”) with IAM Health GmbH […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading